FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550894493> ?p ?o ?g. }

• W2550894493 endingPage "559" @default.
• W2550894493 startingPage "552" @default.
• W2550894493 abstract "Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75. Efficacy and safety were evaluated up to week 40. Fifty-one patients received dose escalation and 43 completed the study. PASI 75 and median improvement rate of PASI score at week 40 were 44% and 70.0%, respectively, showing efficacy in skin symptoms. Efficacies in quality of life, nail psoriasis and joint pain were also obtained. Median serum infliximab level increased from less than 0.1 to 1.1 μg/mL from weeks 0 to 40, showing positive correlation between efficacy and serum infliximab level at week 40. Favorable efficacy was observed in patients with detectable serum infliximab levels (≥0.1 μg/mL) at baseline. Incidences of adverse events, serious adverse events, serious infections and serious infusion reactions were 92%, 10%, 4% and 0%, respectively. No marked difference was observed in both efficacy and safety among psoriasis types. No new safety concerns were observed. Infliximab dose escalation was effective and well-tolerated in psoriasis patients with loss of efficacy to standard-dose therapy, suggesting that dose escalation may be a useful therapeutic option for these patients." @default.
• W2550894493 created "2016-11-30" @default.
• W2550894493 creator A5006153455 @default.
• W2550894493 creator A5052085221 @default.
• W2550894493 creator A5060247604 @default.
• W2550894493 creator A5063280552 @default.
• W2550894493 creator A5068242406 @default.
• W2550894493 date "2016-11-24" @default.
• W2550894493 modified "2023-10-16" @default.
• W2550894493 title "Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study" @default.
• W2550894493 cites W1552422862 @default.
• W2550894493 cites W1580608335 @default.
• W2550894493 cites W1589693489 @default.
• W2550894493 cites W1973064602 @default.
• W2550894493 cites W1986491516 @default.
• W2550894493 cites W1996472975 @default.
• W2550894493 cites W2003904406 @default.
• W2550894493 cites W2010827973 @default.
• W2550894493 cites W2013361256 @default.
• W2550894493 cites W2017082386 @default.
• W2550894493 cites W2019933066 @default.
• W2550894493 cites W2024163966 @default.
• W2550894493 cites W2028096017 @default.
• W2550894493 cites W2030348118 @default.
• W2550894493 cites W2031157372 @default.
• W2550894493 cites W2031349966 @default.
• W2550894493 cites W2033889161 @default.
• W2550894493 cites W2050154180 @default.
• W2550894493 cites W2053691719 @default.
• W2550894493 cites W2054926473 @default.
• W2550894493 cites W2067327580 @default.
• W2550894493 cites W2072640801 @default.
• W2550894493 cites W2094124191 @default.
• W2550894493 cites W2096991001 @default.
• W2550894493 cites W2103524303 @default.
• W2550894493 cites W2118559127 @default.
• W2550894493 cites W2120422600 @default.
• W2550894493 cites W2130698927 @default.
• W2550894493 cites W2137101132 @default.
• W2550894493 cites W2145778588 @default.
• W2550894493 cites W2152262899 @default.
• W2550894493 cites W2166396307 @default.
• W2550894493 cites W2172257129 @default.
• W2550894493 cites W2197700243 @default.
• W2550894493 cites W2462135947 @default.
• W2550894493 cites W4233561050 @default.
• W2550894493 cites W4238258170 @default.
• W2550894493 cites W4249483860 @default.
• W2550894493 cites W71760069 @default.
• W2550894493 doi "https://doi.org/10.1111/1346-8138.13698" @default.
• W2550894493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5434916" @default.
• W2550894493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27882586" @default.
• W2550894493 hasPublicationYear "2016" @default.
• W2550894493 type Work @default.
• W2550894493 sameAs 2550894493 @default.
• W2550894493 citedByCount "26" @default.
• W2550894493 countsByYear W25508944932017 @default.
• W2550894493 countsByYear W25508944932018 @default.
• W2550894493 countsByYear W25508944932019 @default.
• W2550894493 countsByYear W25508944932020 @default.
• W2550894493 countsByYear W25508944932021 @default.
• W2550894493 countsByYear W25508944932022 @default.
• W2550894493 countsByYear W25508944932023 @default.
• W2550894493 crossrefType "journal-article" @default.
• W2550894493 hasAuthorship W2550894493A5006153455 @default.
• W2550894493 hasAuthorship W2550894493A5052085221 @default.
• W2550894493 hasAuthorship W2550894493A5060247604 @default.
• W2550894493 hasAuthorship W2550894493A5063280552 @default.
• W2550894493 hasAuthorship W2550894493A5068242406 @default.
• W2550894493 hasBestOaLocation W25508944931 @default.
• W2550894493 hasConcept C126322002 @default.
• W2550894493 hasConcept C16005928 @default.
• W2550894493 hasConcept C17991360 @default.
• W2550894493 hasConcept C197934379 @default.
• W2550894493 hasConcept C2776260265 @default.
• W2550894493 hasConcept C2777011040 @default.
• W2550894493 hasConcept C2777138892 @default.
• W2550894493 hasConcept C2780564577 @default.
• W2550894493 hasConcept C71924100 @default.
• W2550894493 hasConcept C90924648 @default.
• W2550894493 hasConceptScore W2550894493C126322002 @default.
• W2550894493 hasConceptScore W2550894493C16005928 @default.
• W2550894493 hasConceptScore W2550894493C17991360 @default.
• W2550894493 hasConceptScore W2550894493C197934379 @default.
• W2550894493 hasConceptScore W2550894493C2776260265 @default.
• W2550894493 hasConceptScore W2550894493C2777011040 @default.
• W2550894493 hasConceptScore W2550894493C2777138892 @default.
• W2550894493 hasConceptScore W2550894493C2780564577 @default.
• W2550894493 hasConceptScore W2550894493C71924100 @default.
• W2550894493 hasConceptScore W2550894493C90924648 @default.
• W2550894493 hasIssue "5" @default.
• W2550894493 hasLocation W25508944931 @default.
• W2550894493 hasLocation W25508944932 @default.
• W2550894493 hasLocation W25508944933 @default.
• W2550894493 hasLocation W25508944934 @default.
• W2550894493 hasOpenAccess W2550894493 @default.
• W2550894493 hasPrimaryLocation W25508944931 @default.
• W2550894493 hasRelatedWork W1964002779 @default.

• next